Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results Demonstrating 100% Protection Against Serious Diseases Including Hospitalization
SPAC transactions are coming to a halt amid the SEC’s crackdown, diminishing interest from private investors